NO952129L - Oksalylamino-benzofuran- og benzotienyl-derivater - Google Patents

Oksalylamino-benzofuran- og benzotienyl-derivater

Info

Publication number
NO952129L
NO952129L NO952129A NO952129A NO952129L NO 952129 L NO952129 L NO 952129L NO 952129 A NO952129 A NO 952129A NO 952129 A NO952129 A NO 952129A NO 952129 L NO952129 L NO 952129L
Authority
NO
Norway
Prior art keywords
carbon atoms
formula
stands
branched alkyl
straight chain
Prior art date
Application number
NO952129A
Other languages
English (en)
Other versions
NO952129D0 (no
Inventor
Gabriele Braunlich
Rudiger Fischer
Mazen Es-Sayed
Rudolf Hanko
Stephen Tudhope
Graham Sturton
Trevor Abram
Wendy J Mcdonald-Gibson
Mary F Fitzgerald
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9410863A external-priority patent/GB9410863D0/en
Priority claimed from GB9410891A external-priority patent/GB9410891D0/en
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO952129D0 publication Critical patent/NO952129D0/no
Publication of NO952129L publication Critical patent/NO952129L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Indole Compounds (AREA)
  • Manufacturing Optical Record Carriers (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Photolithography (AREA)

Abstract

Det blir beskrevet oksalylamino-benzofuran- og benzotlenyl-derivater med den generelle formel (I) 0-R. O K, hvor L står for et oksygen- eller svovelaton, R1 står for hydrogen eller rettkjedet eller forgrenet alkyl med opp til 6 karbonatomer eller står for halogen, karboksyl, cyano, nitro, trlfluormetyl eller en gruppe med formel -OR5, -SR6 eller -M7&, R2 står for hydrogen eller rettkjedet eller forgrenet alkyl med opp til 6 karbonatomer, R3 står for hydroksyl, benzyloksy eller rettkjedet eller forgrenet alkyl eller alkoksy son hver har opp til 10 j karbonatoner og som hver eventuelt er mono- til trlsubstltuert, eller står for aryl som har 6 til 10 kar- bonatomer som eventuelt er monosubstltuert til trlsubstltuert, eller står for en gruppe med formelen -K ! eller står for en rest med formelen NH- - l T står for et oksygen- eller svovelatoæ, A står for hydrogen, hydroksyl, cykloalkyl med opp til 6 karbonatomer, l karboksy eller rettkjedet forgrenet alkoksy eller alkoksykarbonyl som hver har opp til 6 karbonatoner, eller ' står for rettkjedet eller forgrenet alkyl eller alkenyl soa hver har opp til 8 karbonatomer og som hver eventuelt kan være monosubstltuert, eller A står for en gruppe med formelen -CONR13>R14', og R4 står for fenyl eller står for en S- til 7-ledds, mettet eller umettet heterocyklus som kan Inneholde opp til 4 oksygen-, svovel- og/eller nltrogenatoner som heteroatomer til hvilken det kan være bundet en ytterligere benzenrlng og hvor alle ringene eventuelt er monosubstltuert til trlsubstltuert, eller R4 står for adamanlyl, cykloalkyl eller cykloalkenyl son hver har opp til 6 karbonatomer, eller salter derav. l : Det blir dessuten beskrevet en fremstilling av disse forbindelsene. Disse forbindelsene er egnet for forhindring og behandling av akutte og kroniske Innenmatorlske prosesser, spesielt l luftveiene.
NO952129A 1994-05-31 1995-05-30 Oksalylamino-benzofuran- og benzotienyl-derivater NO952129L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410863A GB9410863D0 (en) 1994-05-31 1994-05-31 Heterocyclycarbonyl substituted oxalylamino-benzofurane derivatives
GB9410891A GB9410891D0 (en) 1994-05-31 1994-05-31 Oxalylamino-benzofuran-and benzothienyl-derivatives

Publications (2)

Publication Number Publication Date
NO952129D0 NO952129D0 (no) 1995-05-30
NO952129L true NO952129L (no) 1995-12-01

Family

ID=26304969

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952129A NO952129L (no) 1994-05-31 1995-05-30 Oksalylamino-benzofuran- og benzotienyl-derivater

Country Status (29)

Country Link
US (1) US5565488A (no)
EP (1) EP0685474B1 (no)
JP (1) JPH083154A (no)
KR (1) KR950032163A (no)
CN (1) CN1119187A (no)
AT (1) ATE171172T1 (no)
AU (1) AU695464B2 (no)
BG (1) BG99680A (no)
CA (1) CA2150301A1 (no)
CO (1) CO4600675A1 (no)
CZ (1) CZ140895A3 (no)
DE (1) DE69504753T2 (no)
DK (1) DK0685474T3 (no)
EE (1) EE9500034A (no)
ES (1) ES2124461T3 (no)
FI (1) FI952612L (no)
HR (1) HRP950288A2 (no)
HU (1) HUT71597A (no)
IL (1) IL113894A (no)
LV (1) LV11467B (no)
MA (1) MA23603A1 (no)
MY (1) MY130580A (no)
NO (1) NO952129L (no)
NZ (1) NZ272217A (no)
PL (1) PL308825A1 (no)
RO (1) RO113642B1 (no)
SK (1) SK72195A3 (no)
TN (1) TNSN95061A1 (no)
ZA (1) ZA954400B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
US7144885B2 (en) * 2002-02-22 2006-12-05 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
AU2003215380B2 (en) * 2002-02-22 2008-10-02 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
US20040259926A1 (en) * 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
MXPA05013061A (es) * 2003-06-05 2006-03-02 Warner Lambert Co Benzotiofenos sustituidos con cicloalquilos y heterocicloalquilos como agentes terapeuticos.
WO2004108708A1 (en) * 2003-06-05 2004-12-16 Warner-Lambert Company Llc 3-substituted indoles and derivatives thereof as therapeutic agents
MXPA05013210A (es) * 2003-06-05 2006-03-09 Warner Lambert Co Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
WO2004108716A1 (en) * 2003-06-05 2004-12-16 Warner-Lambert Company Llc 3-arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents
JP2006526608A (ja) * 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド
CN1845914A (zh) * 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
CA2666469A1 (en) * 2006-09-01 2008-03-06 Bayer Healthcare Ag Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146243A1 (en) 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
GB9200623D0 (en) * 1992-01-13 1992-03-11 Bayer Ag Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives

Also Published As

Publication number Publication date
IL113894A0 (en) 1995-08-31
FI952612A7 (fi) 1995-12-01
CN1119187A (zh) 1996-03-27
NZ272217A (en) 1997-02-24
ATE171172T1 (de) 1998-10-15
ZA954400B (en) 1996-01-24
CZ140895A3 (en) 1995-12-13
EE9500034A (et) 1995-12-15
EP0685474A1 (en) 1995-12-06
CA2150301A1 (en) 1995-12-01
SK72195A3 (en) 1995-12-06
DE69504753T2 (de) 1999-02-04
CO4600675A1 (es) 1998-05-08
TNSN95061A1 (fr) 1996-02-06
HRP950288A2 (en) 1997-08-31
RO113642B1 (ro) 1998-09-30
MA23603A1 (fr) 1996-04-01
BG99680A (en) 1996-01-31
EP0685474B1 (en) 1998-09-16
PL308825A1 (en) 1995-12-11
LV11467B (en) 1996-12-20
JPH083154A (ja) 1996-01-09
NO952129D0 (no) 1995-05-30
DE69504753D1 (de) 1998-10-22
IL113894A (en) 1999-06-20
AU2028695A (en) 1995-12-07
DK0685474T3 (da) 1999-06-14
AU695464B2 (en) 1998-08-13
MY130580A (en) 2007-06-29
HUT71597A (en) 1996-01-29
FI952612L (fi) 1995-12-01
HU9501569D0 (en) 1995-07-28
KR950032163A (ko) 1995-12-20
ES2124461T3 (es) 1999-02-01
LV11467A (lv) 1996-08-20
FI952612A0 (fi) 1995-05-29
US5565488A (en) 1996-10-15

Similar Documents

Publication Publication Date Title
TW200633990A (en) Amide compound
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
WO2005012269A8 (ja) 新規アゾール化合物
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
DE69736642D1 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
DE60024651D1 (de) Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten
DE69332792T2 (de) 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
WO2005092895A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
UA48937C2 (uk) Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить
DE3876813D1 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
TW200745034A (en) New compounds
HU9503376D0 (en) New thiazolidindiones and drugs containing them
MY139461A (en) Condensed furan compounds
PL1685142T3 (pl) Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera
ATE214697T1 (de) Dibenzodihydropyridincarbonsäureester und ihre anwendung in chemolumineszenz- untersuchungsverfahren
WO2002000638A8 (en) Substituted phthalides as anti-convulsive drugs
HU9300176D0 (en) Method for producing unsaturated 17beta-substituted 3-carboxy steroides
MXPA04005940A (es) Acidos 3-(imidazolil)-2-aminopropanoicos.
EP0885891A4 (en) ISOXAZOLE DERIVATIVES
GB0412314D0 (en) Compounds
ZA9510908B (en) Pharmaceutical compounds
LV11832A (lv) O-acil-4-fenilcikloheksanoli to salis zalu lidzekli kas satur minetas vielas un to pielietojums
CY2225B1 (en) Organic compounds